MedTrace Logo

A Study of Qishenyiqi Dripping Pills in Healthy Participants

NCT04471298 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2021-07-14

No results posted yet for this study

Summary

This study will evaluate the safety and tolerability of Qishenyiqi Dripping Pills in healthy participants, following oral administration with multiple escalating dose of it.

Conditions

  • Healthy Participants

Interventions

DRUG

Qishenyiqi dripping pills, 6 bags

28 consecutive days

DRUG

Qishenyiqi dripping pills, 9 bags

28 consecutive days

DRUG

Qishenyiqi dripping pills, 12 bags

28 consecutive days

DRUG

Qishenyiqi dripping pills placebo, 6 bags

28 consecutive days

DRUG

Qishenyiqi dripping pills placebo, 9 bags

28 consecutive days

DRUG

Qishenyiqi dripping pills placebo, 12 bags

28 consecutive days

Sponsors & Collaborators

  • Tasly Pharmaceutical Group Co., Ltd

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-09-21
Primary Completion
2021-01-11
Completion
2021-01-11

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04471298 on ClinicalTrials.gov